AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of liquid biopsy technologies, has partnered with AstraZeneca PLC (LSE:AZN) to enhance cancer drug development by 'leveraging' the former's DNA damage response assay. Specifically, the collaboration will focus on adapting ANGLE's existing Parsortix-based assay for identifying micronuclei in circulating tumour cells (CTCs), a crucial step in studying DNA damage responses.

ANGLE inks AstraZeneca deal to develop ground-breaking cancer assay

Merck

Pfizer

Big money tends to flow from one sector to the other. During the pandemic, sectors like pharmaceutical and e-commerce were hot.

3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect

Beyond analysts' top -and-bottom-line estimates for Astrazeneca (AZN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics

Barrick Gold

Lockheed Martin

Inflation in the United States has been stubborn and a matter of concern for policymakers. For March, the consumer price increase rose by 3.5% on a year-on-year basis, which was more than expected.

3 Blue-Chip Stocks to Buy as High Inflation Persists

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes?

Astrazeneca (AZN) Could Be a Great Choice

Amgen

Structure Therapeutics Inc

Eli Lilly

Novo Nordisk

Sanofi

Viking Therapeutics

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million. The financing was led by RA Capital Management, and included new investors AstraZeneca (LSE/STO/Nasdaq: AZN) and Bristol Myers Squibb, along with existing investors Janus Henderson Investors, Third Rock Ventures, Wellington Manageme.

Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials

WILMINGTON, Del.--(BUSINESS WIRE)--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC). These results from TOPAZ-1, which are the longest survival follow-up ever reported for a global, randomized Phase III trial in this setting, will be presented on A.

IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

AstraZeneca PLC (LSE:AZN) has been upgraded by a leading investment bank following guidance on the company's dividend policy, and a more positive earnings outlook. Deutsche Bank has moved to 'hold' from 'sell' on stock in the pharma giant as well as raising its price target by 1,00p to 10,500p.

AstraZeneca upgrade (of sorts) by leading investment bank

Bristol-Myers

The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in the economy's resilience.

3 Pharma Stocks That Are Money-Printing Machines in 2024

AstraZeneca PLC (LSE:AZN) is poised to maintain its full-year financial guidance without adjustments when it announces its first-quarter results later this month (April 25), according to insights from Shore Capital, which expects any significant updates to be unveiled at the drugs giant's capital markets day on May 21. The company's cancer drugs, Imfinzi and Imjudo, are expected to show a robust performance, despite mandatory price cuts in Japan affecting the former.

AstraZeneca: A case of steady-as-she-goes, says broker

BAE Systems PLC

British American Tobacco

Diageo

Legal & General Group PLC

National Grid

RELX

Smith & Nephew

Unilever

The list ranks stocks based on their market cap and dividend yield alone. What I am looking for is quality dividend stocks with long track records of progressive dividend growth, and while dividend yield is still important, it's a secondary consideration.

U.K. Top 40 Quality Dividend Stocks: Q2 2024

The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.

AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids

There is no evidence linking diabetes and weight loss drugs like Ozempic and Wegovy to an increase in suicidal thoughts, the European Union's drug regulator said Friday, the latest findings casting doubt on a link after a probe by U.S. regulators said a “small risk” couldn't be ruled out.

No Evidence Linking Ozempic And Suicidal Thoughts, EU Says

It was framed as a pitched battle between two opposing camps in AstraZeneca PLC (LSE:AZN)'s shareholder base. On one side, chief executive Pascal Soriot's 11% annual remuneration hike was egregious, excessive and symbolic of capitalist greed.

Was AstraZeneca boss Soriot's pay rise controversial? Not particularly

AstraZeneca PLC (LSE:AZN) shareholders approved a controversial increase to chief executive Pascal Soriot's pay package yesterday. Over 78% of votes gave the £18.7 million salary and bonus package the nod, representing an 11% year-over-year increase.

AstraZeneca shareholders approve £18.7mln CEO pay package

Astrazeneca (AZN) closed the most recent trading day at $69.45, moving +1.97% from the previous trading session.

Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype.1 FASENRA was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma (SEA) in patients aged 12 and older.1 This additional indication for FASENRA was supported by evidence from TATE, an open-label, multinational, no.

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

AstraZeneca PLC (LSE:AZN) has increased its annual dividend by 7%, bringing it up to $3.10 (£2.5) per share. It marks the highest annual dividend increase in recent years, having only shifted from $2.8 to $2.9 between 2019 and 2023.

AstraZeneca offers 7% dividend sweetener on day of crucial pay vote

AstraZeneca said on Thursday it intends to increase annual dividend for 2024 by 7% to $3.10 per share, betting on strong performance and cash generation on the back of its blockbuster drugs and several recent acquisitions.

AstraZeneca unveils dividend hike ahead of CEO pay vote at AGM

Tomorrow's shareholder vote on AstraZeneca PLC (LSE:AZN) boss Pascal Soriot's compensation represents a microcosm of the broader debate around executive entitlement and the disparity in corporate values on both sides of the Atlantic. Some argue that Soriot's exorbitant pay package is an egregious affront to moral decency, while others, including some of AstraZeneca's own shareholders, point to the US as proof that he's actually underpaid.

AstraZeneca pay debate exposes disparity in US-UK corporate values

STOCKHOLM, SWEDEN / ACCESSWIRE / April 10, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB ("AlzeCure" or "the Company"), a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's disease and pain, today announced that Professor Jan Lundberg invests in the company and is proposed as a new member of the company's board of directors. Professor Jan Lundberg has more than 25 years of experience from leading positions in global pharmaceutical companies, including as global head of research at Astra and then AstraZeneca (1996 - 2009) and global head of research and development at Eli Lilly (2010 - 2018).

Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board

ASML Hld

Hermes International

HSBC Holdings

L'Oreal SA

LVMH Moet Hennessy Louis Vuitton

Nestle SA

Novartis

Prosus NV

Roche Holding AG

SAP SE

Siemens AG

TotalEnergies SE

The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.

Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.

FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.

AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors

News for AstraZeneca Stock (AZN)